The U.S. Food and Drug Administration (FDA) has approved a new cardiac indication for the AdreView (iobenguane I-123 injection) SPECT radiopharmaceutical from GE Healthcare.
The FDA cleared AdreView for the scintigraphic assessment of myocardial sympathetic innervation in the evaluation of patients with New York Heart Association class II or III heart failure and left-ventricular ejection fraction of 35% or less, according to GE.
A limited number of tools are available to help assess cardiac disease progression in heart failure patients, and the new agent can help clinicians understand the potential for progression of heart failure, GE said.
